Exhibit 99.1

  Laserscope Details New, Higher Reimbursement Rate for Its GreenLight PVP(TM)
                        Treatment for Enlarged Prostate

    SAN JOSE, Calif., March 31 /PRNewswire-FirstCall/ -- Laserscope
(Nasdaq: LSCP), a pioneer in the development and commercialization of medical
lasers and advanced fiber-optic devices, said today that the Centers for
Medicare and Medicaid Services (CMS) announced the assignment of the company's
Photoselective Vaporization of the Prostate (PVP(TM)) procedure for the
treatment of Benign Prostatic Hyperplasia (BPH), or enlarged prostate, to New
Technology Ambulatory Payment Classification (APC) 1525 (CMS Transmittal 132,
Publication 100-04).  The new classification carries with it a payment rate of
$3,750.00, approximately twice that of the old rate.

    "We are very pleased with today's news," said Eric Reuter, President and
Chief Executive Officer of Laserscope.  "We believe that the response by the
CMS to our request for a new APC code for our GreenLight PVP procedure,
clearly demonstrates the effectiveness and safety profile that makes this BPH
treatment unique and unlike any other known technology in the world.  The
increased payment rate now more accurately reflects the costs of performing
the procedure.

    "We expect that the new payment rate dictated by the CMS will encourage
performance of the PVP procedure at those hospitals, where previously, due to
economics, it would not have been made available to patients," continued
Mr. Reuter.  "We plan to provide additional details and revised guidance for
the remainder of 2004 in the near future."

    The company said that effective April 1, 2004, according to the CMS, PVP
procedures performed in an outpatient hospital site of service should be coded
using new Healthcare Common Procedure Coding System (HCPCS) code C9713 and
will be grouped to APC 1525.  The description for HCPCS code C9713 is
"non-contact laser vaporization of prostate, including coagulation control of
intraoperative and post-operative bleeding."  The minimum unadjusted
co-payment amount for the procedure is $750.00.  In addition, non-contact
laser vaporization has an "S" payment status, which means that the multiple
procedure discount does not apply to PVP.

    About Laserscope

    Laserscope designs, manufactures, sells and services on a worldwide basis
an advanced line of medical laser systems and related energy delivery devices
for the physician office, outpatient surgical center, and hospital markets.
More information about Laserscope can be found on the Company's web site at
www.laserscope.com .

    Except for historical information presented, the matters discussed in this
announcement may contain forward-looking statements that are subject to
certain risks and uncertainties that could cause actual results to differ
materially from those projected.  These risks are detailed from time to time
in the Company's public disclosure filings with the U.S. Securities and
Exchange Commission (SEC).  Copies of Laserscope's public disclosure filings
with the SEC, including the most recent Annual Report on Form 10-K and the
most recent forms 10-Q are available upon request from its Investor Relations
Department.

    For further information please contact: Eric Reuter, President & CEO, or
Dennis LaLumandiere, CFO, both of Laserscope, +1-408-943-0636; or Tricia Ross,
Analysts, or Laurie Berman, General Inquiries, both of Financial Relations
Board, +1-310-407-6555, for Laserscope

SOURCE  Laserscope
    -0-                             03/31/2004
    /CONTACT:  Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, both
of Laserscope, +1-408-943-0636; or Tricia Ross, Analysts, or Laurie Berman,
General Inquiries, both of Financial Relations Board, +1-310-407-6555, for
Laserscope/
    /Web site:  http://www.laserscope.com /
    (LSCP)

CO:  Laserscope; Centers for Medicare and Medicaid Services
ST:  California
IN:  HEA MTC BIO
SU:  PDT